1-6 of 6
Naveed Shaik
Close
Sort by
Journal Articles

Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients

Swan Lin, PharmD, M. Naveed Shaik, PhD, Geoffrey Chan, MD, Jorge E. Cortes, MD, Ana Ruiz-Garcia, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1450.
https://doi.org/10.1182/blood-2018-99-111132
Published: 2018
Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 258.
https://doi.org/10.1182/blood.V130.Suppl_1.258.258
Published: 2017
Journal Articles

A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Jorge E. Cortes, MD, Florian H. Heidel, MD, Michael Heuser, MD, Walter Fiedler, MD, B. Douglas Smith, MD, Tadeusz Robak, MD, Pau Montesinos Fernandez, MD, Weidong Wendy Ma, PhD, M. Naveed Shaik, PhD, Mirjana Zeremski, MD, Ashleigh O'Connell, Geoffrey Chan, MD
Journal: Blood
Blood (2016) 128 (22): 99.
https://doi.org/10.1182/blood.V128.22.99.99
Published: 2016
Journal Articles

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Clinical Trials & Observations
John P. Leonard, Ann S. LaCasce, Mitchell R. Smith, Ariela Noy, Lucian R. Chirieac, Scott J. Rodig, Jian Q. Yu, Shankar Vallabhajosula, Heiko Schoder, Patricia English, Donna S. Neuberg, Peter Martin, Michael M. Millenson, Scott A. Ely, Rachel Courtney, Naveed Shaik, Keith D. Wilner, Sophia Randolph, Annick D. Van den Abbeele, Selina Y. Chen-Kiang, Jeffrey T. Yap, Geoffrey I. Shapiro
Journal: Blood
Blood (2012) 119 (20): 4597–4607.
https://doi.org/10.1182/blood-2011-10-388298
Published: 2012
Includes: Supplemental data
Journal Articles

Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies

Catriona Jamieson, Jorge E. Cortes, Vivian Oehler, MD, Michele Baccarani, MD, Hagop M. Kantarjian, Cristina Papayannidis, Kristen N. Rice, MD, Xiaoxi Zhang, Naveed Shaik, Rachel Courtney, PhD, Wendy J. Levin, MD, MS, Giovanni Martinelli, MD
Journal: Blood
Blood (2011) 118 (21): 424.
https://doi.org/10.1182/blood.V118.21.424.424
Published: 2011
Journal Articles

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Ruben Niesvizky, MD, Suzanne Lentzsch, MD, PhD, Ashraf Z. Badros, MD, Asher A. Chanan-Khan, MD, Seema B. Singhal, MD, Jeffrey A. Zonder, MD, Ravi Vij, MBBS, MD, Xiangao Huang, PhD, Maurizio DiLiberto, PhD, Rachel Courtney, PhD, M. Naveed Shaik, PhD, Sindy T. Kim, BS, Sophia Randolph, MD, PhD, Scott A Ely, MD, MPH, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2010) 116 (21): 860.
https://doi.org/10.1182/blood.V116.21.860.860
Published: 2010